Newsquawk Logo

Boston Scientific (BSX) enters into a USD 2bln accelerated share repurchase agreement; expects net impact of USD 0.02 to adj. EPS in FY26; will have USD 3bln remaining under share repurchase authorisation after the ASR

Boston Scientific's announcement of a $2 billion accelerated share repurchase agreement is likely to boost investor confidence, as it signals strong cash flow and commitment to returning capital to shareholders.

Newsquawk StaffPublished On the live feed at — 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Pakistan has deployed jet squadron, 8000 troops and an air defence system to Saudi Arabia under the defence pact, according to security officials and government sources

US BROKER MOVES: VFC double upgraded at Williams Trading; AMAT downgraded at Morgan Stanley

Boston Scientific (BSX) enters into a USD 2bln accelerated share repurchase agreement; expects net impact of USD 0.02 to adj. EPS in FY26; will have USD 3bln remaining under share repurchase authorisation after the ASR

Rosatom head says the Zaporizhzhia nuclear power plant situation is rapidly approaching the point of no return, IFX reports

IMF upgrades the UK's 2026 GDP view to 1.0% (prev. 0.8%). Risks to growth are tilted to the downside.

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

The anticipated impact of $0.02 to adjusted EPS in FY26 is modest but reinforces a positive outlook on profitability, particularly with $3 billion left under their repurchase authorization. Investors should watch for potential upward price support and increased interest among healthcare equities, given the broader context of capital returns in the sector.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.